Nissha Co.ltd. · TSE:7915
Nissha Co.ltd — Investor Presentation (July 2026)
28 slides from Nissha Co.ltd's investor presentation, Jul 7, 2026
Slide 1: Management Briefing: Reinforcing and Rationalizing the Business Portfolio
Management Briefing Reinforcing and Rationalizing the Business Portfolio Medical Devices CDMO Update July 7, 2026 Nissha Co., Ltd.
Slide 2: Today's Agenda
Today's Agenda ⚫Reinforcing and Rationalizing the Business Portfolio ⚫Medical Devices CDMO Update ⚫Medical Segment Update ©2026 Nissha Group 2
Slide 3: Reinforcing and Rationalizing the Business Portfolio
Reinforcing and Rationalizing the Business Portfolio Junya Suzuki Chairman of the Board and Group CEO Nissha Co., Ltd.
Slide 4: Nissha's Characteristics
Nissha's Characteristics ⚫ B2B, manufacturer of intermediate components & materials ⚫ CDMO business model (Contract Design/Development and Manufacturing) ⚫ Global supply to global leading companies ⚫ Core technologies for processing ⚫ Business (Product) Portfolio Strategy ⚫ Launch new products in ex
Slide 5: Reinforcing and Rationalizing the Business Portfolio: Disciplined diversification
As previously disclosed on February 12, 2026 Reinforcing and Rationalizing the Business Portfolio: Disciplined diversification 2010s 2020s（through the present） Toward 2030 Overreliance Building a business portfolio through Selective and on the IT devices selective focus and diversification disciplin
Slide 6: Selective and Disciplined Diversification
Selective and Disciplined Diversification Standing on Growth Potential and Profitability High Star Problem Child Medical Devices CDMO Pharmaceuticals Medical Medical Devices CDMO Mobility Exterior (Americas) CDMO Molded Parts (Asia) Functional Components Growth potential Film-touch Sensors Mobility
Slide 7: Investing in High-Profitability and High-Growth Business (Medical)
Investing in High-Profitability and High-Growth Business (Medical) Capital Reallocation through Operating CF and Exits/Divestitures Capacity Expansion Value-Added Enhancement OTC Pharmaceuticals CDMO Medical Devices CDMO ⚫ 1-plant to 2-plant production ⚫ Strengthen design & development capabilities
Slide 8: Profitability Improvement through Business Portfolio Management
Profitability Improvement through Business Portfolio Management ⚫ Profitability improvement through strategic investment in high-profitability businesses centered on Medical and downsizing low-growth and low-profitability businesses Harvest Returns on Investment ⚫ Value-added enhancement of 2026 med
Slide 9: Medical Devices CDMO Strategy Updates
Medical Devices CDMO Strategy Updates Brandon Hoffman Senior Vice President Medical Technologies Business Unit CEO, Nissha Medical Technologies
Slide 10: Medical Segment: Products and Services
Medical Segment: Products and Services Pharmaceuticals Medical Devices Medical Devices CDMO Medical Devices (CDMO*) (Own Brand) CDMO 13% 2025 20% Sales 50% 54,109 Millions of JPY Pharmaceuticals (CDMO*) Business Media 17% Business Media Medical Devices Own Brand * CDMO：Contract Design/Development an
Slide 11: Medical Devices CDMO: Our Roles
Medical Devices CDMO: Our Roles One-stop service provider from design to manufacturing Medical Devices OEMs (Major Global Companies) Distribution Marketing Design Development Verification Manufacturing Sales Product concepts Outsource Products Design Development Verification Manufacturing Medical De
Slide 12: High Growth in the Medical Devices CDMO Market
High Growth in the Medical Devices CDMO Market ⚫ Global medical devices CDMO market is growing faster than the overall medical device market, and our target segment shows strong growth potential Market Growth Our Focus with Strong Growth Global Medical Devices Market *1 Cardiovascular Devices CAGR (
Slide 13: Medical Devices CDMO Sales Breakdown by Application
Medical Devices CDMO Sales Breakdown by Application Drug Delivery Systems Others 17% Cardiovascular Devices Cardiovascular Drug Devices Delivery 31% Robotics 2% Robotics Medical Devices 3% CDMO Surgical Navigation JPY27,356M 5% FY2025 Surgical Devices Patient Monitoring Surgical Devices 11% 31% ©202
Slide 14: Footprint in the U.S., a Medically Advanced Country
Footprint in the U.S., a Medically Advanced Country ⚫ Adjacent to and jointly developing with U.S. medical devices OEM New Richmond, WI Norwalk, OH Miniaturization Metal Processing Buffalo, NY Headquarters Sandpoint, ID Automation Nashville, TN R&D Colorado Springs, CO Steerability Small Batch Produ
Slide 15: Megatrends in the U.S. Medical Devices OEM Outsourcing
Megatrends in the U.S. Medical Devices OEM Outsourcing ⚫ Post-Covid priorities for supply chain reliability, coupled with geopolitical tensions, are accelerating the regionalization of supply chains and partially reversing globalization ⚫ Bridging competency gaps due to convergence of technologies i
Slide 16: Converging Technology is Driving Innovation
Converging Technology is Driving Innovation Healthcare Pathway Long Term Focus ⚫ Diagnosis Digital Surgery/Smart Device Medical Industry ⚫ Treatment ⚫ Robotic platforms ⚫ Post procedure ⚫ Navigation ⚫ Chronic care ⚫ Visualization ⚫ Data collection Targeted Healthcare Benefits ⚫ Connectivity Digital
Slide 17: Our Focus with Unique Differentiation Capabilities
Our Focus with Unique Differentiation Capabilities Foundational Capabilities Unique Differentiation Capabilities Molding Metal Processing Miniaturization Steerability Technologies Translation to Clinical Application Contribution to New Focus Existing Focus Existing Minimally Invasive Devices Cardiov
Slide 18: Nissha Technology Hub Nashville
Nissha Technology Hub Nashville ⚫ Technology development and translation to clinical application, driving concept development to commercialization Integrated Technology Hub Seamlessly connects research, development, and clinical validation for concept R&D Facility on Vanderbilt Univ. Campus Direct a
Slide 19: Scaling Micro Molding Facility
Scaling Micro Molding Facility ⚫ New ~50,000 sq ft facility under construction; targeted completion April 2027 Strong Demand Visibility Order backlog up 86% since the 2024 acquisition New facility at New Richmond, WI Expected Impact Proximity to Minneapolis, a global hub for medical devices OEMs Ali
Slide 20: Extended Opportunities of Micro Molding Capability
Extended Opportunities of Micro Molding Capability Medical Opportunities AI/Data Center Opportunities Cannulas for Market Connectors for Market Diagnostics and Drug Delivery (2025) * Data Centers (2025) * ⚫ Micro requirements in diabetes management driven by patient comfort $ 2.0B ⚫ Strong demand gr
Slide 21: Programs in Pipeline Securing Our Growth
Programs in Pipeline Securing Our Medical Devices CDMO Growth ⚫ Increasing opportunities in accordance with our enhanced CDMO capabilities and the market trend ⚫ Numerous programs in our pipeline are enabling growth for the medium term Programs in Pipeline Sales Contribution by Programs in Pipeline
Slide 22: Profitability Initiatives
Profitability Initiatives ⚫ Reinforce the CDMO business expansion and operational improvements CDMO Business Expansion Operational Improvements ⚫ CMO vs CDMO ratio helps the Production Improvements profitability, in addition to increase the 1 ⚫ Automation CDMO business volume +JPY 200 ⚫ Workforce En
Slide 23: Projection of growth and profitability
Projection of growth and profitability ⚫ Sales growth contributed by the programs in pipeline ⚫ EBITDA target 17.1% in 2027 ⚫ Sales growth CAGR 8.5% ⚫ Shift to more CDMO 32,200 24.0% programs 32,000 30,000 22.0% 2025→2027 ⚫ Profitability 27,356 27,000 improvement initiatives +3.8 pp 20.0% 18.0% 22,0
Slide 24: Medical Segment Update
Medical Segment Update Wataru Watanabe Director of the Board Senior Executive Vice President Chief Strategy Officer Nissha Co., Ltd.
Slide 25: Medical Segment
Medical Segment ⚫ 2026 Q1: Integrating Medical Technologies business and Pharmaceuticals into Medical Segment Before Medical Technologies Others Growth 13% Area Medical Medical Star Devices Business Pharmac Devices Others CDMO Own Media euticals FY2025 Brand 20% Sales 50% Reclassified JPY 54.1 bn Af
Slide 26: Medical Segment: Business Projection
Medical Segment: Business Projection ⚫ Sales growth accelerated by Medical Devices CDMO and Pharmaceuticals CDMO ⚫ Operating profit continues to improve, reaching 10% over in 2027 Medical Segment Sales Medical Segment Operating Profit (Millions of JPY) 12% 60,000 CAGR 8.5% 56,800 60,600 10% 54,109 1
Slide 27: Creating Global Connection of Strategic Assets for Medical Devices
Creating Global Connection of Strategic Assets for Medical Devices ⚫ Reconfiguring Strategic Assets (Capabilities) across the Group China Mold Tools and Molded Parts Japan United States Medical Devices CDMO Medical Devices CDMO (Biomaterials) R&D Molded Parts Vietnam Medical Devices Malaysia Molded
Slide 28: The information contained in this presentation and provided at the financial results briefings and
The information contained in this presentation and provided at the financial results briefings and conferences, other than historical facts such as performance targets, plans, forecasts, strategies, and other forward-looking information, is based on information currently available and judgments deem